HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 288/6/C1390    most recent 00353.2004v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Bouley, R. Articles by Ausiello, D. A. Search for Related Content PubMed PubMed Citation Articles by Bouley, R. Articles by Ausiello, D. A.

RECEPTORS AND SIGNAL TRANSDUCTION

Downregulation of the vasopressin type 2 receptor after vasopressin-induced internalization: involvement of a lysosomal degradation pathway

Program in Membrane Biology and Renal Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts

Submitted 20 July 2004 ; accepted in final form 12 January 2005

Vasopressin (VP) increases urinary concentration by signaling through the vasopressin receptor (V2R) in collecting duct principal cells. After downregulation, V2R reappears at the cell surface via an unusually slow (several hours) "recycling" pathway. To examine this pathway, we expressed V2R-green fluorescent protein (GFP) in LLC-PK1a cells. V2R-GFP showed characteristics similar to those of wild-type V2R, including high affinity for VP and adenylyl cyclase stimulation. V2R-GFP was located mainly in the plasma membrane in unstimulated cells, but it colocalized with the lysosomal marker Lysotracker after VP-induced internalization. Western blot analysis of V2R-GFP showed a broad 57- to 68-kDa band and a doublet at 46 and 52 kDa before VP treatment. After 4-h VP exposure, the 57- to 68-kDa band lost 50% of its intensity, whereas the lower 46-kDa band increased by 200%. The lysosomal inhibitor chloroquine abolished this VP effect, whereas lactacystin, a proteasome inhibitor, had no effect. Incubating cells at 20°C to block trafficking from the trans-Golgi network reduced V2R membrane fluorescence, and a perinuclear patch developed. Cycloheximide reduced the intensity of this patch, showing that newly synthesized V2R-GFP contributed significantly to its appearance. Cycloheximide also inhibited the reappearance of cell surface V2R after downregulation. We conclude that after downregulation, V2R-GFP is delivered to lysosomes and degraded. Reappearance of V2R at the cell surface depends on new protein synthesis, partially explaining the long time lag needed to fully reestablish V2R at the cell surface after downregulation. This degradative pathway may be an adaptive response to allow receptor-ligand association in the hypertonic and acidic environment of the renal medulla.

lysosome; trafficking; vasopressin receptor in LLC-PK1 cells

This article has been cited by other articles:

				F. Conti, S. Sertic, A. Reversi, and B. Chini Intracellular trafficking of the human oxytocin receptor: evidence of receptor recycling via a Rab4/Rab5 "short cycle" Am J Physiol Endocrinol Metab, March 1, 2009; 296(3): E532 - E542. [Abstract] [Full Text] [PDF]

				M. K. Raychowdhury, A. J. Ramos, P. Zhang, M. McLaughin, X.-Q. Dai, X.-Z. Chen, N. Montalbetti, M. del Rocio Cantero, D. A. Ausiello, and H. F. Cantiello Vasopressin receptor-mediated functional signaling pathway in primary cilia of renal epithelial cells Am J Physiol Renal Physiol, January 1, 2009; 296(1): F87 - F97. [Abstract] [Full Text] [PDF]

				I. Schwieger, K. Lautz, E. Krause, W. Rosenthal, B. Wiesner, and R. Hermosilla Derlin-1 and p97/Valosin-Containing Protein Mediate the Endoplasmic Reticulum-Associated Degradation of Human V2 Vasopressin Receptors Mol. Pharmacol., March 1, 2008; 73(3): 697 - 708. [Abstract] [Full Text] [PDF]

				R. A. Fenton, L. Brond, S. Nielsen, and J. Praetorius Cellular and subcellular distribution of the type-2 vasopressin receptor in the kidney Am J Physiol Renal Physiol, September 1, 2007; 293(3): F748 - F760. [Abstract] [Full Text] [PDF]

				C. S.-L. Gal, D. Raufaste, S. Derick, J. Blankenstein, J. Allen, B. Pouzet, M. Pascal, J. Wagnon, and M. A. Ventura Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R938 - R949. [Abstract] [Full Text] [PDF]

				X. Yi, R. Bouley, H. Y. Lin, S. Bechoua, T.-x. Sun, E. del Re, T. Shioda, M. K. Raychowdhury, H. A. J. Lu, A. B. Abou-Samra, et al. Alix (AIP1) is a vasopressin receptor (V2R)-interacting protein that increases lysosomal degradation of the V2R Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1303 - F1313. [Abstract] [Full Text] [PDF]